SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001720725-20-000058
Filing Date
2020-11-05
Accepted
2020-11-05 16:03:40
Documents
54
Period of Report
2020-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q oyst-20200930.htm   iXBRL 10-Q 1086999
2 EX-31.1 oyst-q3x20ex311.htm EX-31.1 12104
3 EX-31.2 oyst-q3x20ex312.htm EX-31.2 12269
4 EX-32.1 oyst-q3x20ex321.htm EX-32.1 7867
5 EX-32.2 oyst-q3x20ex322.htm EX-32.2 6936
  Complete submission text file 0001720725-20-000058.txt   4691624

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT oyst-20200930.xsd EX-101.SCH 31054
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT oyst-20200930_cal.xml EX-101.CAL 71771
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT oyst-20200930_def.xml EX-101.DEF 143247
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT oyst-20200930_lab.xml EX-101.LAB 430533
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT oyst-20200930_pre.xml EX-101.PRE 281388
11 EXTRACTED XBRL INSTANCE DOCUMENT oyst-20200930_htm.xml XML 720342
Mailing Address 202 CARNEGIE CENTER SUITE 109 PRINCETON NJ 08540
Business Address 202 CARNEGIE CENTER SUITE 109 PRINCETON NJ 08540 (609) 382-9032
Oyster Point Pharma, Inc. (Filer) CIK: 0001720725 (see all company filings)

IRS No.: 811030955 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39112 | Film No.: 201290367
SIC: 2836 Biological Products, (No Diagnostic Substances)